Pfizer scored new Crohn’s data that could give its Remicade biosimilar, Inflectra, more oomph for its market-share fight, one of the first U.S. head-to-heads…

AbbVie’s former blockbuster AndroGel faces a class-action lawsuit over side effects—and a trial of a different sort as new testosterone-replacement data paint…

Will Valeant price its new psoriasis med at a discount to rivals to reflect its hefty suicide risk-management program? And if not, can it still compete?…

A Genentech lobbyist who generated enormous sales for the company allegedly kept millions in consulting payments to himself.

Greek prosecutors have raided Novartis offices and questioned 178 people in a bribery investigation launched after corruption allegations surfaced in local…

The FDA’s promotional enforcement squad wasn’t very active in 2016—until December, that is. This month, they've cited six drugmakers, more than half the…

Years after wrapping up Abilfy marketing allegations with the U.S. Justice Department, Bristol-Myers Squibb agreed to pay $19.5 million to settle similar…

Beating the street to market painkillers in Chicago? You might need a special license for that soon.